The initials “tPA” stand for tissue Plasminogen Activator, and it is a concentrated form of the body’s own natural clot-dissolving enzyme. An early product of the biotech revolution in the 1980s, the ...

In the not-so-distant past, doctors treated strokes in an after-the-fact way. A stroke did its damage, and then—if the ...

In 1995, the U.S. Food and Drug Administration (FDA) approved the first clot-busting agent for ischemic strokes, named tissue-type plasminogen activator (tPA). Shortly after its approval, researchers ...

The Spurs announced the diagnosis on Wednesday. The Spurs organization had closed ranks around Popovich since he went ...

IV tissue plasminogen activator (tPA) is a safe and effective therapy for acute ischemic stroke when administered within established time windows. The main complication from administration of tPA ...

Other common causes include protein S deficiency, tissue plasminogen activator (TPA) deficiency, activated protein C resistance, and type 1 plasminogen activator (PAI-1) defects (Table I).

According to the results, tissue plasminogen activator (tPA) activates plasminogen to form plasmin, which cleaves the precursor of brain-derived neurotrophic factor (BDNF) to release the mature ...

For further clarification, consult your healthcare provider. This medication is an enzyme (tissue plasminogen activator (tPA)), prescribed for heart attack, stroke, and pulmonary embolism.